MA53980A - Anticorps spécifiques de l'apoj glycosylée et leurs utilisations - Google Patents
Anticorps spécifiques de l'apoj glycosylée et leurs utilisationsInfo
- Publication number
- MA53980A MA53980A MA053980A MA53980A MA53980A MA 53980 A MA53980 A MA 53980A MA 053980 A MA053980 A MA 053980A MA 53980 A MA53980 A MA 53980A MA 53980 A MA53980 A MA 53980A
- Authority
- MA
- Morocco
- Prior art keywords
- apoj
- glycosyl
- antibodies specific
- antibodies
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18382752 | 2018-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53980A true MA53980A (fr) | 2022-01-26 |
Family
ID=64426823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053980A MA53980A (fr) | 2018-10-23 | 2019-10-23 | Anticorps spécifiques de l'apoj glycosylée et leurs utilisations |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210388108A1 (fr) |
EP (1) | EP3870614A1 (fr) |
JP (1) | JP2022506108A (fr) |
KR (1) | KR20210081397A (fr) |
CN (1) | CN113366021A (fr) |
AU (1) | AU2019365391A1 (fr) |
BR (1) | BR112021006516A2 (fr) |
CA (1) | CA3115887A1 (fr) |
IL (1) | IL282384A (fr) |
MA (1) | MA53980A (fr) |
MX (1) | MX2021004684A (fr) |
SG (1) | SG11202103124WA (fr) |
WO (1) | WO2020083979A1 (fr) |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0435911B1 (fr) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (fr) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Vecteurs de transformation de la levure yarrowia |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
CA2116774C (fr) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression dans e. coli de fragments d'anticorps ayant au moins une cysteine presente sous forme de thiol libre. utilisation pour la production d'anticorps f(ab') bifonctionnels |
ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
ITRM20040098A1 (it) * | 2004-02-25 | 2004-05-25 | Univ Roma | Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi. |
US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
ES2364169B1 (es) * | 2010-02-09 | 2012-07-10 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Titular al 50%) | Uso de las isoformas de apo j como biomarcadores de lesión tisular. |
CA2868391A1 (fr) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprenant du n1-methyl-pseudouracils et methodes pour les preparer |
WO2017139975A1 (fr) * | 2016-02-19 | 2017-08-24 | Huiru Wang | Anticorps dirigés contre la n-acétylglucosamine et la n-acétylgalactosamine |
EP3232200A1 (fr) * | 2016-04-12 | 2017-10-18 | Institut Catalá De Ciencies Cardiovasculars (ICCC) | Procédés et kits pour le diagnostic et la stratification de risque de patients atteints d'ischémie |
-
2019
- 2019-10-23 EP EP19802086.9A patent/EP3870614A1/fr active Pending
- 2019-10-23 BR BR112021006516-4A patent/BR112021006516A2/pt unknown
- 2019-10-23 US US17/287,777 patent/US20210388108A1/en active Pending
- 2019-10-23 CA CA3115887A patent/CA3115887A1/fr active Pending
- 2019-10-23 JP JP2021523276A patent/JP2022506108A/ja active Pending
- 2019-10-23 AU AU2019365391A patent/AU2019365391A1/en not_active Abandoned
- 2019-10-23 KR KR1020217015370A patent/KR20210081397A/ko active Search and Examination
- 2019-10-23 SG SG11202103124WA patent/SG11202103124WA/en unknown
- 2019-10-23 WO PCT/EP2019/078855 patent/WO2020083979A1/fr unknown
- 2019-10-23 MX MX2021004684A patent/MX2021004684A/es unknown
- 2019-10-23 CN CN201980069358.0A patent/CN113366021A/zh active Pending
- 2019-10-23 MA MA053980A patent/MA53980A/fr unknown
-
2021
- 2021-04-18 IL IL282384A patent/IL282384A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020083979A1 (fr) | 2020-04-30 |
EP3870614A1 (fr) | 2021-09-01 |
US20210388108A1 (en) | 2021-12-16 |
IL282384A (en) | 2021-06-30 |
BR112021006516A2 (pt) | 2021-07-13 |
KR20210081397A (ko) | 2021-07-01 |
MX2021004684A (es) | 2021-06-04 |
AU2019365391A1 (en) | 2021-04-29 |
JP2022506108A (ja) | 2022-01-17 |
CN113366021A (zh) | 2021-09-07 |
CA3115887A1 (fr) | 2020-04-30 |
SG11202103124WA (en) | 2021-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
MA52426A (fr) | Conjugués d'il-15 et leurs utilisations | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
MA42808A (fr) | Anticorps de liaison à l'il-8 et leurs utilisations | |
MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA53168A (fr) | Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations | |
MA49457A (fr) | Molécules d'anticorps se liant à cd73 et leurs utilisations | |
MA47130A (fr) | Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations | |
MA52022A (fr) | Anticorps qui se lient à cd39 et leurs utilisations | |
MA52414A (fr) | Anticorps agonistes de pd-1 et leurs utilisations | |
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA52970A (fr) | Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations | |
MA54539A (fr) | Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA43308A (fr) | Molécules d'anticorps se liant à april et leurs utilisations | |
MA53122A (fr) | Variants d'anticorps cd38 et leurs utilisations | |
MA54955A (fr) | Anticorps anti-claudine 6 et leurs utilisations | |
MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
MA52094A (fr) | Anticorps anti-il-27 et leurs utilisations |